SLC16A1: A Protein Involved in Brain Function and Drug Targeting

Target Name: SLC16A1

NCBI ID: G6566

SLC16A1

SLC16A1: A Protein Involved in Brain Function and Drug Targeting

SLC16A1 is a protein that is expressed in various tissues throughout the body. It is a member of the Solute carrier family 16, which is a large family of transmembrane proteins that play a critical role in the transport of a wide variety of molecules across cell membranes. SLC16A1 is primarily expressed in the brain, where it is involved in the transport of various neurotransmitters, including dopamine, serotonin, and GABA.

SLC16A1 is a protein that is known for its unique structure and biology. It is a member of the SLC transmembrane protein family, which is characterized by the presence of a transmembrane region that is involved in the protein's stability and its ability to interact with various ligands on the outside of the cell membrane. SLC16A1 has a unique structure that is characterized by a long extracellular domain and a short intracellular domain. The long extracellular domain is involved in the protein's stability and its ability to interact with various ligands on the outside of the cell membrane, while the short intracellular domain is involved in the protein's localization and stability within the cell.

SLC16A1 is also involved in several different signaling pathways in the brain. For example, it is involved in the regulation of neurotransmitter release from dopamine-producing neurons, and it is also involved in the regulation of the uptake and release of serotonin and GABA by these neurons. In addition, SLC16A1 is also involved in the regulation of the release of endogenous opioids by the hypothalamus, and it is thought to play a role in the development and maintenance of pain.

SLC16A1 is also a potential drug target in the brain. The neurotransmitters that it is involved in the regulation of, such as dopamine, serotonin, and GABA, are known to play a critical role in the pathophysiology of a wide variety of psychiatric and neurological disorders, including depression, anxiety, and pain. As such, SLC16A1 is a potential target for the development of new treatments for these disorders.

In addition to its involvement in the regulation of neurotransmitter release, SLC16A1 is also involved in the regulation of the transport of other molecules across cell membranes. For example, it is known to be involved in the transport of glutamate, a neurotransmitter that is involved in many different signaling pathways in the brain, and it is also involved in the transport of other molecules, such as GABA and endogenous opioids.

SLC16A1 is also thought to play a role in the regulation of inflammation in the brain. For example, it is known to be involved in the regulation of the production of pro-inflammatory cytokines by immune cells in the brain, and it is also involved in the regulation of the production of anti-inflammatory cytokines by these cells. These cytokines play a critical role in the regulation of immune responses and inflammation, and as such, SLC16A1 is thought to play an important role in the regulation of brain inflammation.

In conclusion, SLC16A1 is a protein that is involved in the regulation of a wide variety of physiological processes in the brain. Its unique structure and biology, as well as its involvement in several different signaling pathways and its potential as a drug target make it an important molecule to study. Further research is needed to fully understand the role of SLC16A1 in the regulation of brain function and the development of new treatments for psychiatric and neurological disorders.

Protein Name: Solute Carrier Family 16 Member 1

Functions: Bidirectional proton-coupled monocarboxylate transporter (PubMed:12946269, PubMed:33333023, PubMed:32946811). Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, acetate and the ketone bodies acetoacetate and beta-hydroxybutyrate, and thus contributes to the maintenance of intracellular pH (PubMed:12946269, PubMed:33333023). The transport direction is determined by the proton motive force and the concentration gradient of the substrate monocarboxylate. MCT1 is a major lactate exporter (By similarity). Plays a role in cellular responses to a high-fat diet by modulating the cellular levels of lactate and pyruvate that contribute to the regulation of central metabolic pathways and insulin secretion, with concomitant effects on plasma insulin levels and blood glucose homeostasis (By similarity). Facilitates the protonated monocarboxylate form of succinate export, that its transient protonation upon muscle cell acidification in exercising muscle and ischemic heart (PubMed:32946811). Functions via alternate outward- and inward-open conformation states. Protonation and deprotonation of 309-Asp is essential for the conformational transition (PubMed:33333023)

The "SLC16A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets